Jump to main content
Jump to site search

MedChemComm

Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry

Research Article

Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors

*
Corresponding authors
a
Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, USA
E-mail: brian.sparling@amgen.com
b
Department of Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, USA
c
Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, USA
d
Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 360 Binney Street, Cambridge, USA
e
Department of Molecular Engineering, Amgen Inc., 360 Binney Street, Cambridge, USA
Med. Chem. Commun., 2017, Advance Article

DOI: 10.1039/C6MD00578K
Received 14 Oct 2016, Accepted 30 Nov 2016
First published online 02 Dec 2016

This article is part of themed collection: New Talent: Americas
Please wait while Download options loads
 
 
This article has not yet been cited.

Supplementary Info